J Clin Endocr Metab:AMH水平与女性生育能力无关

2015-09-29 MedSci MedSci原创

J Clin Endocrinol Metab:抗穆氏管荷尔蒙的水平与机体的剩余能力并无关联据发表于Clinical Endocrinology & Metabolism的一项新的研究表明,存在一或两次流产史的育龄女性,较低或较高的抗穆氏管荷尔蒙的水平与其生育能力并无关联。研究人员表示,其研究结果并不支持年轻的育龄女性在孕前咨询时常规应用抗穆氏管荷尔蒙(AMH)测试。Enrique F.

据发表于Clinical Endocrinology & Metabolism的一项新的研究表明,存在一或两次流产史的育龄女性,较高或较低的抗苗勒氏管激素(AMH)水平与其生育能力并无关联。


研究人员表示,其研究结果并不支持年轻的育龄女性在孕前咨询时常规进行AMH测试。

Enrique F. Schisterman博士及其同事评估了来自阿司匹林对妊娠及生殖能力(EAGeR)影响试验的数据,该试验纳入了1202名年龄在18-40岁存在一或两次流产史的女性,所有研究对象均积极尝试受孕以证实AMH对其受孕能力的影响。

孕前AMH的水平(< 1 ng/mL; n = 124)定义为低水平的,(参照; 1 to 3.5 ng/mL; n = 595)正常的,(> 3.5 ng/mL; n = 483)高水平的。

66%的AMH水平较低的研究对象接受人绒毛膜促性腺激素检测妊娠,相比之下,AMH正常的为65.2%,AMH较高的为65.2%。

与水平正常以及水平较低的AMH (受孕能力OR = 1.13; 95% CI, 0.85-1.49)相比,水平较高的AMH (受孕能力OR = 1.04; 95% CI, 0.87-1.24)与机体的受孕能力并无关联。

较低或较高水平的AMH与(活产数、流产次数以及上次流产时间分析受限后)接受人绒毛膜促性腺激素检测或临床检查证实受孕之间并无显著关联。

最后,研究人员写道,“因此,AMH似乎对育龄女性的孕前咨询并无效果,尽管进一步的研究或可阐明AMH在受孕能力不明确、无流产史或不存在复发性流产史的女性中有一些作用。”

原始出处:

Zarek SM, et al.  Anti-Müllerian hormone levels not associated with fertility. J Clin Endocrinol Metab. 2015;doi:10.1210/jc.2015-2474.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895839, encodeId=3c431895839e5, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Mar 27 11:33:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062431, encodeId=409a206243131, content=<a href='/topic/show?id=4c3d241806' target=_blank style='color:#2F92EE;'>#AMH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2418, encryptionId=4c3d241806, topicName=AMH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Mar 24 03:33:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887466, encodeId=3bcd188e46632, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Nov 04 09:33:00 CST 2015, time=2015-11-04, status=1, ipAttribution=)]
    2016-03-27 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1895839, encodeId=3c431895839e5, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Mar 27 11:33:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062431, encodeId=409a206243131, content=<a href='/topic/show?id=4c3d241806' target=_blank style='color:#2F92EE;'>#AMH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2418, encryptionId=4c3d241806, topicName=AMH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Mar 24 03:33:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887466, encodeId=3bcd188e46632, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Nov 04 09:33:00 CST 2015, time=2015-11-04, status=1, ipAttribution=)]
    2016-03-24 fengyi812
  3. [GetPortalCommentsPageByObjectIdResponse(id=1895839, encodeId=3c431895839e5, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Sun Mar 27 11:33:00 CST 2016, time=2016-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062431, encodeId=409a206243131, content=<a href='/topic/show?id=4c3d241806' target=_blank style='color:#2F92EE;'>#AMH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2418, encryptionId=4c3d241806, topicName=AMH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Thu Mar 24 03:33:00 CST 2016, time=2016-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887466, encodeId=3bcd188e46632, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Wed Nov 04 09:33:00 CST 2015, time=2015-11-04, status=1, ipAttribution=)]
    2015-11-04 guojianrong

相关资讯

JCEM:GnRHa治疗期间AMH不能反应卵巢储备功能

促性腺激素释放激素激动剂(GnRHa)被实验性用于保护接受化疗年轻女性癌症患者的生育能力。抗苗勒氏管激素(AMH)是由卵巢颗粒细胞产生,可以作为卵巢储备功能的标志,但是在GnRHa治疗期间这项指标是否有用尚不清楚。为了确定长效GnRHa对AMH水平的影响,来自美国麻省总医院Hadine Joffe教授及其团队进行了一项研究,该研究发现GnRHa治疗期间AMH不是卵巢储备功能的一个可靠指标。该研究结